Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.

Date publication

mars 2022

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PREVOST Alain , Pr WESTEEL Virginie

Tous les auteurs :
Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35260342

Résumé

Roughly 20% of patients with non-small-cell lung cancer exhibit locally advanced, unresectable, stage III disease. Concurrent platinum-based chemoradiotherapy is the backbone treatment, which is followed by maintenance immunotherapy, yet with poor long-term prognosis. This phase II trial (IFCT-0803) sought to evaluate whether adding cetuximab to cisplatin and pemetrexed chemoradiotherapy would improve its efficacy in these patients.

Mots clés

CPNPC de stade III, Cetuximab, Chimioradiothérapie concomitante, Cisplatin, Cisplatine, Concurrent chemoradiotherapy, Cétuximab, Pemetrexed, Pémétrexed, Stage III NSCLC

Référence

Cancer Radiother. 2022 Mar 5;: